Introduction
Tumor antigens are generally weakly immunogenic and T-cell responses can be subject to toleragenic pressure 1 . To avoid this, vaccines have been designed as conjugates of tumor antigens with immunogenic molecules such as KLH 2 . Conjugation captures the large undamaged CD4+ T-cell repertoire, providing T-cell help for the anti-tumor immune responses 2, 3 . Idiotypic (Id) Ig-KLH vaccines aimed to suppress B-cell tumors via an anti-Id response are one example of the promise of this approach 4, 5, 6 . We have used a similar strategy to deliver Id fusion proteins via DNA vaccines 7, 8 . The Id is composed of tumor-derived single chain Fv (scFv) and is linked to the Fragment C (FrC) of tetanus toxin. DNA vaccines encoding Id-FrC fusion proteins induce high levels of anti-Id antibody and protective immunity against B-cell lymphoma 9 .
Continuous suppression of lymphoma cell growth is likely to require maintenance of antibody levels. Although long-lived plasma cells can secrete antibody for extended periods 10 , memory B cells are also required. Survival factors for memory B cells are unclear but antigen appears unnecessary 11, 12 . For antibody responses induced by conjugate vaccines, the question of the effect of confronting memory B cells with free unconjugated "helpless" antigen, potentially derived from residual or emergent tumor, arises. In the case of Id antigen, or for carbohydrate antigens, this led to dramatic loss of memory B cells 13 . We found previously that the major fraction of the IgG component of the memory B-cell response induced by a DNA Id-FrC fusion vaccine was completely and specifically silenced by Id protein alone 14 . In contrast, Id protein coupled to FrC protein rescued and boosted the anti-Id IgG response, indicating the critical importance of CD4 + T-cell help for maintenance of the memory B-cell response.
We have now shown that silencing of the anti-Id IgG response by unconjugated antigen is permanent, but the surprising observation was that the IgM response appeared relatively unscathed. To assess the wider applicability of these findings, and to investigate the effects of antigen on memory B cells at different maturational stages, we have used a model antigen, the well-defined hapten NP (4-hydroxy-3-nitrophenyl) acetyl-carrier model. Clearly, NP itself is unlikely to induce CD4+ T-cell responses whereas the carrier protein will, mimicking the situation with Id antigen. Also there is a relatively high frequency of NP-specific B cells within the natural B-cell repertoire in wild type C57/BL6 mice and these can be tracked using antigen 15, 16 . We show that, in the absence of T-cell help, silencing of a proportion of IgG+ve memory B cells occurs in this model and that it is permanent. In contrast, co-existing IgM+ve memory B cells show only transient silencing, but appear unable to regenerate a high affinity IgG response. The NP model allowed the further conclusion that the key distinguishing feature appears to be affinity for antigen, with rheostatic control of the fate of memory B cells which, in the absence of T-cell help, allows only low affinity, mainly IgM+ve, B cells to survive. It also confirms the generality of the findings which likely apply to all weak immunogens, especially tumor antigens.
Materials and methods

Proteins and immunisation
In the Id model, C57BL/KaLwRij mice (8-12 weeks old) were given priming injections of 25 μg of p.Id-FrC DNA vaccine into each rear anterior tibialis muscle where indicated injections of 50 μg Id Ig were administered subcutaneously (sc) six weeks later. Id Ig was purified from sera of 5T33 tumor-bearing mice using a G-protein column. Where indicated a booster injection was given sc with 100 μg Id-FrC fusion protein. The Id-FrC fusion protein was generated in 293f cells (Invitrogen) and purified using an anti-FrC antibody affinity column.
In the NP model C57BL/6 mice (8-12 weeks old) were primed by intraperitoneal (ip) injection with 100 μg of NP 16 -KLH (Biosearch Technologies, USA) in alum; where indicated mice were also boosted intravenously (iv) with 20 μg of NP 16 -KLH six weeks later or at times indicated. In suppression experiments after immunisation with NP 16 -KLH mice received 200 μg of "helpless" antigen NP conjugated to mouse serum albumin (NP-MSA) or MSA (Invitrogen) as a control sc. NP-MSA was prepared as described 17 . 
Adoptive transfer
In the Id model, donor mice were immunised with DNA vaccine and then injected with 50 μg Id Ig 6-7 weeks later. After a further three weeks B cells were purified using a B-cell separation kit (Miltenyi) following the manufacturer's instruction. T cells were purified from FrC-primed mice using a T-cell separation kit (Miltenyi). B and T cells were injected iv into RAG2KO mice. Individual mice received a total of 1x10 7 B cells and 4×10 6 T cells. The recipients were boosted with 100 μg of Id-FrC protein iv one week later and bled after a further one week. Anti-Id and FrC antibodies were measured by ELISA.
In the NP model, for establishing B-cell memory, donor mice were primed and boosted with NP 16 -KLH as described 18 . Three weeks after boost they received either 200 μg NP-MSA (mouse serum albumin) or the same amount of MSA alone. After a further two weeks, 5×10 6 B cells purified as above were transferred into C57Bl/6 recipient mice primed with 100 μg KLH in alum. For NP, it was not necessary to use RAGKO recipients since, in contrast to Id, the higher frequency of NP-specific memory B cells did not require the homeostatic expansion of injected cells for detection. One week later the recipients were boosted with 20μg NP 16 -KLH iv. and bled after a further one week. Antibody responses were measured by ELISA.
Detection of antibody and antigen-specific B cells
Anti-Id antibody levels were measured by ELISA as described 14 . For NP ELISA plates were coated with 5 μg/ml of NP 16 -BSA (bovine serum albumin, Biosearch Technologies) and then the same protocol used for Id antigen was followed. For IgM anti-mouse IgM antibody (Sigma) was used at 1/1000 dilution. Antigen-specific B cells secreting IgM and IgG were measured by ELISPOT. Briefly, 96-well plates (Millipore, MAIPS4510) were coated with either the Fab fragment of 5T33Id IgG (1 μg/ml) or FrC (3 μg/ml) or NP 16 -BSA (5 μg/m) overnight in sterile PBS. To validate the specificity of NP responses, control plates were coated with 5 μg/ml BSA with subsequent sample incubation. Plates were blocked using RPMI1640 supplemented with 10% FCS. Splenocytes were plated at varying densities and incubated overnight in RPMI1640 supplemented with 10% FCS, 2-mercaptoethanol, penicillin and streptomycin. Horseradish peroxidase-labelled anti-mouse IgG (The Binding Site, Birmingham, U.K.) or anti-IgM antibody (Sigma) was used for detection with a subsequent incubation with 3-amino-9-ethylcarbazole (Sigma) for 10 min. Spots were enumerated using an ELISPOT reader (AID, Strabberg, Germany). The values were plotted as the number of antibody secreting cells (ASC) per million lymphocytes following subtraction of non-specific background values.
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Detection of NP-specific memory B cells
Mice were primed with NP 16 -KLH in alum followed by a booster injection seven weeks later. For detection of memory B cells, splenic lymphocytes were harvested 3 weeks after the last injection. The cells (5×10 6 ) were initially preincubated with CD16/32 blocking antibody (clone 93, eBiosciences) at 1 μg per 10 6 cells. This was followed by staining with anti-IgD FITC (clone 11-26c), anti-CD19 PerCP-Cy5.5 (clone eBio1D3) (both eBiosciences), anti-IgG1 APC (clone X56, BD Bioscience), biotinylated anti-IgM (clone R6-60.2, BD) antibodies and incubation with 1-2 μg NP 25 -PE (Biosearch) for 40 min on ice. This was followed by incubation with streptavidin-PE-Cy7 (BD). . FACS analysis was performed using a FACS Canto with FACS Diva software (BD).
Antibody affinity
The affinity of NP-specific IgG and IgM was expressed using a formula: affinity = U/ml to NP 4 -BSA/ U/ml to NP 16 -BSA. Binding to each molecule (coated at 5μg/ml to ELISA plates) was determined by ELISA and expressed in units relative to a known standard. For IgM affinity, serum samples were mildly treated with 2-mercaptoethanol (Sigma) followed by blocking of released SH groups with iodoacetamide (Sigma) as described 19, 20 . Sample dilutions were then incubated with plates for 2h at room temperature. This was followed by secondary antibodies as above.
V H gene analysis
For V H -gene analysis mice were primed and boosted with NP 16 -KLH as above and then given a second booster injection of NP 16 -KLH three weeks after. Spleens were harvested three days later and stained with NP 25 -PE and anti-CD138 APC-labelled antibody (clone 281-2, BD). NP-specific plasmablasts were sorted as a NP surface positive, CD138 + population from three mouse spleens. Bulk sorting was performed using a FACS Aria and cells were used for RNA purification. RNA was purified from a total of 10 5 cells using the Rneasy kit (Qiagen). cDNA was produced using the Superscript II first strand synthesis kit (Invitrogen) with random hexamers. The cDNA was used as template for V-gene amplification by Hot star Taq polymerase (Promega) using a framework one forward J588a primer or primer mix A, B and C (supplementary Fig 1) C. Purified PCR products was ligated into pGEM-T vector (Promega) followed by transformation into competent E.coli (XL-1 blue strain). DNA sequencing was carried out on 48 IgG and 36 IgM colonies. Sequencing reactions were run on an ABI3130xl genetic analyser and the data was analysed using MacVector software.
Statistical analysis
Statistical analysis was performed using the Mann-Witney test. P values in the range 0.05>p>0.01 were assigned as one star, in the range 0.01>p>0.001 were two stars.
Results
Contrasting effects of "helpless" antigen on the IgM and IgG responses against Id Ig
A DNA vaccine encoding Id scFv fused to FrC (p.Id-FrC) was used to establish a conventional IgG anti-Id antibody response, detectable at seven weeks post priming as serum antibody (Fig. 1A) . At this stage, the majority of germinal centres have contracted and B-cell memory is established 15 . ASC were detectable in the spleens post challenge with Id-FrC protein (Fig. 1C) . Following an injection of unconjugated Id antigen six weeks after priming, both antibody ( Fig. 1A) and ASC (Fig. 1C) were reduced to undetectable levels. When suppressed mice were challenged with conjugated Id (Id-FrC) three days after giving Id antigen they also failed to produce significant IgG antibody (Fig. 1A) .
Data on the IgG response confirm previous findings 14 , but can be contrasted with the lack of effect of the same suppressive procedure on the IgM response. Serum anti-Id IgM was clearly detectable seven weeks post priming (Fig. 1B) . Splenic IgM+ve ASCs (Fig. 1D) were also detectable following challenge with Id-FrC protein (Fig. 1D) . However, injection of unconjugated Id failed to reduce either antibody or ASCs (Fig. 1B, D) . In fact, surviving IgM+ve B cells were able to boost serum IgM levels following an injection of conjugated Id antigen (Fig. 1B) , showing that functional memory cells remained. The fact that most of the IgG response was lost indicates that few of the IgM+ve B cells were capable of switching, at least by 1 week post injection of conjugate.
To assess the fate of B cells of each isotype following confrontation with "helpless" antigen, purified B cells from suppressed or control mice were transferred into RAG2KO recipients together with carrier-primed (FrC) CD4+ T cells. One week later the ability of transferred B cells to respond to Id-FrC protein conjugate was measured in comparison with an unboosted control. No Id-specific IgG was detected in unboosted controls in either group ( Fig. 2A) . Upon booster injection IgG anti-Id antibody was clearly produced by nonsuppressed B cells ( Fig. 2A) , with 10/10 responders producing antibody with a median level of 4917 U/ml. However suppressed B cells ( Fig. 2A) , produced significantly less IgG anti-Id antibody, with 4/10 non-responders, 4 low responders (<700 U/ml) and 2 responders with levels comparable to the nonsuppressed group. The median level of antibody in the suppressed group was 292 U/ml, ~17 fold less than in the non-suppressed group (p<0.01).
The IgM anti-Id response detected in parallel was also low in unboosted mice in both groups (Fig. 2B ). After boosting with Id-FrC conjugate, levels in nonFor personal use only. on August 16, 2017 . by guest www.bloodjournal.org From suppressed mice were enhanced, with 9/9 responders and a median level of 8775 U/ml (Fig. 2B ). However, in contrast to the IgG response, suppressed B cells were also able to produce an anti-Id IgM after boosting, with 11/11 responders and a median level of 9825 U/ml (Fig. 2B ). For IgM, the levels in the non-suppressed or suppressed groups were not significantly different (p>0.05). These data show that the loss of the IgG+ve B cells is irreversible but that the transferred IgM+ve B cells had been largely unaffected by exposure to "helpless" Id antigen.
Induction of IgG and IgM memory antibody responses against NP
A different antigen (NP) was then investigated, both to assess the generality of the findings, and to probe the nature of the antibody responses. The first question was whether NP conjugated to KLH could induce a detectable secondary IgM response, in parallel with an IgG response. Priming with NP-KLH, followed after 6 weeks by iv boosting with the same antigen, induced anti-NP serum antibody of both IgG (Fig. 3A) and IgM ( Fig. 3B) isotypes. Both responses increased by week 1 (Fig. 3A , B), and remained high for the 3 week period of analysis. A control injection of NP-KLH into unprimed mice produced a low level primary response of IgG and IgM antibodies over the same period (Fig. 3A, B) . The results were paralleled by splenic ASC with the IgG response peaking at d6 while IgM response peaked at d4 and fell rapidly by d8 (Fig. 3C, D) , again with insignificant levels induced by a booster injection only. These findings indicate that IgM+ve B cells, detectable in the spleen, form part of the memory response.
Effect of "helpless" antigen on NP-specific memory IgG and IgM B cells
Splenic memory B cells are clearly able to respond to a booster injection of NP-KLH and the next question was the effect on these B cells of removing the KLH component of the conjugate thereby exposing them to "helpless" antigen. To address this we injected NP coupled to the autologous protein MSA (NP-MSA) at week 6. This was followed by a conventional booster injection of NP-KLH 2 or 8 weeks later, with a subsequent measurement of ASC levels at day 4.
Direct effects in immune mice
The effect of NP-MSA on the IgG response mirrored that found previously for Id 14 i.e. almost complete loss of the ASCs. This had occurred by 2 weeks after injection (Fig. 4A ) and was still evident at 8 weeks (Fig. 4B) . Control MSA had no effect. In contrast, the IgM responses, although reduced at the 2 week (Fig. 4C) , recovered by 8 weeks (Fig. 4D) to levels similar to mice injected with MSA alone. It appeared therefore that, while IgG+ve B cells were silenced by soluble "helpless" NP-MSA antigen, IgM+ve B cells were only reduced transiently, with recovery to non-suppressed levels. Since the injection of NP-KLH alone into naïve mice induced no significant IgM responses at this time point (Fig. 4C, D) , recovery appears to be via reversal of the transient suppression of the IgM+ve memory B cells. The failure to detect IgG+ve B cells again suggests that the splenic IgM+ve B cells do not undergo significant switch to IgG following the boosting injection with NP-KLH.
To further confirm the finding that IgG+ve NP-specific B cells were permanently removed after NP-MSA injection we employed FACS analysis for direct detection of NP-specific B cells. Mice were primed and boosted with NP-KLH and given NP-MSA or MSA only (controls) three weeks after the boost and analysed after a further six days. To identify memory B cells we gated on CD19 21 and then analyzed the IgD+ve (for IgM+ve cells) 22 and IgDve (for IgG+ve) populations 21 for antigen binding and for expression of the predominant IgG subclass, IgG1 (Fig. 4E) .
. A representative FACS profile shows that IgG1+ve NP-specific memory B cells (149 per 10 6 lymphocytes) could be detected in the control mouse (Fig. 4Ei) . The test mouse, injected with NP-MSA (Fig 4Eii) , had 40 IgG1+ve NP-specific B cells, indicating a ~4 fold decrease. In contrast the IgG1-ve, NP-binding population did not decrease significantly with 168 cells per 10 6 in the test mouse ( Fig. 4Eii ) and 181 in the control (Fig 4Ei) . Further analysis revealed that IgG1-ve, NPbinding population expressed IgM in both control and test mice ( Fig 4E iii and  iv) . Figure 4F shows data compiled from groups of mice treated as in Figure 4E . The data confirm that the levels of the IgG1+ve, NP-binding memory B cells in the test group that received NP-MSA (n=8, median of 30 per 10 6 lymphocytes) were significantly lower (p<0.01) than that in the control group (n=5, median of 160). The IgG-ve (IgM) NP-binding cell numbers in contrast were comparable, with a median of 271 in mice that received NP-MSA versus 311 in the controls (p>0.05). These data indicate that injection of NP-MSA has caused loss of the majority of the IgG+ve NP-specific memory B cells from the spleen while IgM+ve cells were relatively unaffected.
The IgM+ve B cell population will necessarily include naïve B cells and it was possible that some could recognize the NP-PE antigen 22, 23 . To determine the level of these in the repertoire, we measured antigen-binding IgM+ve B cells in the spleens of naive mice.
A minor population (25-40 cells/10 6 lymphocytes) was detected, which could account for only <20% of the total antigen-binding B cells. It is clear therefore that the majority of antigenspecific IgM+ve B cells which resist exposure to NP-MSA are memory B cells.
Effects revealed by adoptive transfer
To assess the long-term effects of exposure to "helpless" antigen on B cells expressing IgG or IgM, adoptive transfer was used. B cells were isolated from mice primed and boosted with NP-KLH and then injected with NP-MSA (suppressed) or no protein (non-suppressed). Cells were then transferred into recipients primed with KLH/alum alone (Fig 5) . Each recipient group was divided into two, with one group receiving a booster injection of NP-KLH and another being an unboosted control. One week later serum NP-specific IgG and IgM were measured. In both unboosted groups the levels of IgG and IgM antibodies remained similarly low between suppressed and non-suppressed Fig. 5A and B) . In boosted groups IgG responses were reduced from a median of 19,250 U/ml in the non-suppressed group to 12,250 U/ml in the suppressed group (p<0.05), although, in contrast to the Id model, a proportion of B cells able to produce IgG antibody remained significant (Fig. 5A ). For IgM, there was no detectable effect of the prior injection of donors with NP-MSA, with similar levels in both suppressed (34,000 U/ml) and nonsuppressed mice (25,300 U/ml). The conclusion is that, in the NP model, the effect of "helpless" antigen exposure in the donors has been to partially deplete the IgG response, but not to affect the IgM response. Since affinity for antigen may differ in the two isotypic populations, the next question was the role of affinity in determining survival or loss of the memory B cells.
Loss of memory B cells depends on affinity for antigen.
The NP model allows analysis of the binding affinity of the induced antibodies 18, 24 . Highly haptenated antigen (NP16) binds to both low and high affinity Ig, whereas less haptenated antigen (NP4) binds only to high affinity Ig. For an equivalent assessment of IgG and IgM, it was necessary to reduce the pentameric IgM to monomer (see Methods). Pooled serum IgG taken three weeks after a booster injection of NP-KLH, bound similarly to either NP4 or NP16 (Fig. 6A ) with or without reduction indicating that most of the IgG was of high affinity and reduction did not affect binding to NP. In contrast, for IgM, this destroyed almost all the NP4 binding, with no significant effect on NP16 binding (Fig. 6B) . Binding affinities can be expressed as a ratio of binding of NP4 to NP16 of ~1 for IgG and ~0.02 for IgM at week 1 (Fig. 6C, D) , decreasing only slightly at week 3 (Fig. 6C, D) . These data from individual mice confirm the overall findings on pooled sera (Fig. 6A, B) in showing a large difference in affinity between the two isotypes.
The next question concerned the affinity of the small population of IgG+ve memory B cells which had escaped silencing by "helpless" antigen. For this, we analyzed the IgG antibody induced following adoptive transfer of memory B cells exposed to "helpless" antigen (Fig. 5A) . The first observation unrelated to suppression was of an overall reduction of antibody affinity in the recipients (median 0.4) (Fig. 6E) in comparison with the donors (median 1.0) (Fig. 6C) . This is likely due to the fact that only memory B cells are transferred, whereas serum of the donors contains IgG from bone marrowderived plasma cells, potentially of higher affinity 18 .
The ratios of binding to NP4 and NP16 showed that the surviving IgG+ve B cells were capable of producing only low affinity antibody (median 0.05), ~ten-fold lower that non-suppressed B cells (Fig. 6E ). This ratio is in the same range as the levels measured in the IgM response in the donors (Fig. 6D) . The findings indicate that suppression has dramatically affected the affinity of the IgG response, reducing it to the range of the largely unaffected IgM response. The fact that this fraction of the IgG response can escape suppression points to affinity rather than isotype as a determinant of survival. It was not possible to probe for IgM affinity as the binding to NP4 after reduction was too low for analysis in both groups.
Analysis of somatic mutations in anti-NP V H sequences
To gain further insight into the nature of the IgG and IgM memory responses we performed V H sequence analysis. For the NP-specific IgG antibody response, there is a characteristic V H gene usage with certain somatic mutations known to be associated with increased affinity [25] [26] [27] . To analyse V H genes, IgG+ve and IgM+ve memory B cells in immune mice were differentiated by booster injection and after 3 days splenic plasmablasts were FACS sorted using anti-CD138 and NP-PE to identify a double positive population (see Methods). Sequencing of 36 IgG-derived V H -Cγ amplificates from 4 PCR reactions showed all to be mutated (mean=4.4%) ( Table 1 ). Among these were 22 separate clones, with additional intraclonal variants. Analysis of the clones confirmed the known preferential usage of the V1-72 gene (13/22) 25 , with additional usage of V14-3 and a few other individual V H genes ( Table 1 ). The 29 IgM-derived V H -Cμ amplificates contained 17 separate clones, most being mutated but with lower levels (mean=0.8%). The IgM-derived clones showed a similar profile of the preferential usage of V1-72 (6/17), with a proportion using V14-3 (Table 1 ).
Further analysis of the V1-72-derived clones indicated that the D gene, D1-1 (DFL16.1) was the most common in both isotypes, with DQ52 found in a minority (Table 2 ). Three J genes (J1, J2 and J4) were identified. The signature mutation associated with increased affinity for NP lies at position 33 in CDR1 (W to L) 26 . This was found in 9/13 IgG-derived clones (69%) and in 4/6 (67%) IgM-derived clones. A second alteration, considered to arise during VDJ recombination and also associated with increased affinity, lies at position 99 (Y to G) 28 . This was detected in 4/13 IgG-derived clones but was not found in IgM, possibly due to the smaller cohort ( Table 2 ). As reported previously the two changes were always found in separate clones. Overall, the level of mutation differs between the isotypes but the pattern of mutations was similar.
To probe the relationship between the IgG+ve and IgM+ve B-cell populations, we sought clonal identity by analyzing CDR3 sequences. We detected one V1-72-DFL16.1-J1 sequence where common truncations and N-additions at the D-J junction indicate a shared clonal origin of IgG and IgM-derived sequences (Fig. 7) . Clonal relationships were consolidated by common mutational changes in other parts of the VDJ sequences, including at position 33 W to L (Fig. 7) . A second case involved a V1-72-DQ52-J1 sequence, with very close similarity between intraclonal variants of an IgM-derived sequence and the corresponding IgG-derived sequences. Similarity was revealed by Ninsertions at the V-D boundary, together with shared base changes at other positions (Fig. 7) . These examples reveal co-existence of IgG and IgM isotypic variants of a common parental B cell.
Discussion
Targeting cell surface molecules by passive antibody has clear value in the clinic, and the approach of active vaccination to induce and maintain antibody levels is attractive. Induction of antibody against weakly immunogenic tumor antigens, such as Id or Muc1, usually requires activation of T-cell help via conjugation to strong immunogens 2, 29, 30 . This appears also to be the case for prophylactic vaccines against polysaccharides of pathogens such as Streptococcus pneumoniae 31, 32 , which may not elicit adequate T-cell help. Various vaccination strategies can therefore induce high levels of antibody, and plasma cells may persist for some time. However it is likely that memory B cells are required for maintenance of antibody production. In our study we have not investigated the longevity of surface Ig-ve plasma cells, but have focused instead on the memory B cell population. Our concern was that for cancer, and possibly for some infections, release of unconjugated "helpless" antigen could occur naturally and may affect memory B cells.
We found previously using Id antigen that the entire anti-Id memory IgG B-cell response induced by a DNA Id-FrC fusion vaccine is completely and specifically silenced by unconjugated Id Ig 14 . To extend the concept to other antigens, we have reproduced these findings in the NP model. Adoptive transfer in both systems revealed that a significant proportion of antigenexposed IgG+ve memory B cells is lost. In our setting, germinal centers would be expected to have contracted 15 . However the effect on memory B cells appears similar to that observed in germinal centers 33, 34 .
In contrast to IgG+ve B cells, transferred IgM+ve B cells survive, but the key to survival is not in the isotype expressed, but in the affinity for antigen. In the NP system, it was possible to compare affinities of IgG with monomeric IgM, thereby reflecting the status of cell surface IgM. It is clear that the IgM anti-NP response is of low affinity, whereas the majority of the IgG response is of high affinity. The small population of IgG+ve memory B cells which survives exposure to "helpless" antigen was of low affinity, revealing this rather than isotype as the determinant. Analysis of somatic mutations supported the link between mutational level and affinity. However, the signature W to L mutation in CDR1 which increases affinity by 10-100 fold 26 was observed in IgM+ve clones, indicating that this change does not take affinity to the threshold of vulnerability.
Until recently, the IgG isotype has largely served as a memory marker in mice 15, 35, 36 . However, this is not the case for human B cells [37] [38] [39] , and evidence is mounting for the existence of T-dependent IgM+ve memory B cells in mice, possibly with a lower level of somatic mutation 40 . The origin and behavior of these cells is of interest for immunotherapeutic strategies, since IgM antibody could attack tumor cells. One possibility is that they derive from the marginal zone 41 with some being capable of entering follicles and undergoing somatic mutation 42 . When formed these IgM+ve memory B cells appear to be scattered in follicles 43 . This differs from their IgG+ve counterparts which are clustered in close proximity to contracted germinal centres 43 .
Recently a new mouse model of memory B-cell labelling revealed long term IgM+ve B cells induced by a particulate T-dependent antigen. These displayed both a GC and non-GC phenotype and co-existed with IgG+ve B cells 44 . The IgM+ve population responded to antigenic challenge, producing IgM+ve and IgG+ve centroblasts and some IgM-secreting plasmacytes. A soluble antigen (NP-CGG), although differing in the longevity of induced GC structures, also induced IgM+ve memory B cells. Analysis of the intronic sequences of the IgM V H genes revealed that 22-51% were mutated at variable levels. The findings argue for a post GC origin and do suggest that at least a proportion of the formed IgM+ve memory B cells retain the ability to undergo isotype switch.
Our findings are in line with this model in that the IgM+ve memory cells which survive "helpless" antigen exposure appear capable of secreting IgM. It is an open question whether IgM antibody of low affinity but high avidity can be useful in attacking pathogens or cancer cells and it would be useful to investigate this in patients.
Switch events can certainly occur but may generate IgG+ve B cells of low affinity which also survive, but, as in the model, secretion of IgG is not detectable.
Support for the ability of at least a proportion of memory IgM+ve B-cells to contribute to the isotype switched memory pool has been recently reported 22 . The capacity to switch appeared to be influenced by the affinity of co-existing antibody, with high affinity being inhibitory 22 . This could be a factor in our system, but, even if IgM+ve cells were able to switch after antibody has declined, a practical question is whether any of these cells can undergo further affinity maturation, or if naïve B cells have to be activated by further vaccination.
The new insights indicate that vaccination with conjugated tumor antigens is likely to be effective only in patients in remission. If successful, there should be no problem for maintenance of memory. However, if tumor emerges, unconjugated antigen could attack high affinity memory B cells. A simple strategy to bypass this would be to maintain T-cell help by repeated injections of conjugated antigen, possibly with long term expression via adjuvant depots or via DNA delivery. The benefits of repeated vaccinations have been seen already in one study where patients became anti-Id antibody positive with prolonged vaccination 45 .
Author's contributions:
NS designed, performed experiments and wrote the manuscript, MS and AS performed experiments, GB analysed data, FKS designed experiments and wrote the manuscript. (10 7 ) from either suppressed or non-suppressed donor mice were mixed with 4×10 6 FrCprimed purified CD4+ T-cells and injected into Rag2KO recipients. One week after transfer, mice in each recipient cohort were divided into two groups and one was challenged with 100 μg Id-FrC fusion protein (suppressed n=10, nonsuppressed n=9). The remaining groups were unchallenged controls. Mice were bled a week later and sera were analysed for anti-Id IgG (A) and IgM (B) by ELISA. The horizontal bars are median values. These are combined data of two independent experiments. Two stars indicate statistical significance with p<0.01, n/s is non-significant. 6 purified B cells from either suppressed or non-suppressed donor mice were transferred into recipients primed with KLH in alum. One week after, the recipient mice were challenged with 20 μg NP-KLH (suppressed n=11, non-suppressed n=10) and serum samples were analysed for IgG (A) and IgM (B) by ELISA after further one week. One star indicates statistical significance with p<0.05, n/s is non-significant. These are combined data of two independent experiments. Figure 6 . Characterisation of affinity of memory IgG and IgM antibodies. NP-specific antibody affinity was measured by binding to either highly haptenated antigen (NP16) (total Ig affinity) or less haptenated antigen (NP4) (high affinity Ig). Sera were mildly treated by 2-mercapto-ethanol (2-ME) to reduce pentameric IgM. Mice were primed and boosted with NP-KLH and affinity was measured with or without 2-ME in pooled sera samples three weeks after boost (A, B) or individual samples taken at 1 or 3 weeks after boost (C, D). A and B are representative of two independent experiments. C and D are combined data of two independent experiments. (E) Affinity of IgG in suppressed and non-suppressed groups in samples from the adoptive transfer experiments shown in Figure 5 . The samples were taken one week after challenge with NP-KLH following an adoptive transfer on week prior to challenge. Horizontal bars are median values. Two stars indicate statistical significance with p<0.01. These are combined data of two independent experiments. 
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